Evidence map›Paper›PMID 42168673›Full record

ArticleEJNMMI research2026

From imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response.

Yubo Wang, Zhiheng Yao, Jingjing Wan, Yuan Cai, Xinyu Yang, Rongliang Wu, Kebir Sied, Tao Sun, Ying Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yubo Wang *Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Zhiheng Yao *Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Jingjing Wan *Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, Guangdong Province, China.
Yuan CaiGCP-compliant Phase I Clinical Trial Ward, Shenzhen Third People's Hospital, The Second Affiliated Hospital of Southern, University of Science and Technology, Shenzhen, Guangdong, China.
Xinyu YangDepartment of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Rongliang WuDepartment of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Kebir Sied *Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147, Essen, Germany. sied.kebir@uk-essen.de.
Tao Sun *Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. tao.sun@siat.ac.cn.
Ying Liang *Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. liangying@cicams-sz.org.cn.ORCID http://orcid.org/0009-0002-7004-0676

Funding

Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province 2023B1212060052National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen E010224003
6 · The paper itself

Abstract

backgroundRisk of disease progression varies substantially among advanced non-small cell lung cancer (NSCLC) patients who achieve a partial response to initial therapy, and this subgroup currently lacks practical prognostic tools. This study aimed to develop a novel imaging biomarker by assessing bone marrow kinetic heterogeneity via pretreatment dynamic

resultsThe bootstrap-LASSO-Cox analysis identified the slope of the bone marrow free FDG TAC between 10 and 30 min post-injection (BM_C

conclusionFor advanced NSCLC patients achieving an initial partial response, pretreatment assessment of bone marrow kinetics via dynamic

Indexed as

Bone marrowNon-small cell lung cancerPET/CTTreatment response

Identifiers

PMID42168673
PMCPMC13194849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.